Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities

Not checked yet

• All 17 figure captions were read; figure pixels and the native journal PDF/layout were not viewed.
• Supplementary Figures 1–2, Tables 1–6, the Reporting Summary and 17 statistical source-data files were not acquired.
• Patient-specific supplementary metadata and private clinical charts were not acquired.
• External cohort originals and raw data were not read in this lane. Survival-curve participant counts, hazard ratios and confidence intervals are not established by the supplied text.
• GEO GSE252608/GSE252455, BioStudies S-BIAD565 and figshare 10.6084/m9.figshare.24915633 are availability statements; datasets were not downloaded or audited.
• The interactive imaging browser was not opened. Linked code and the patent original were not retrieved or run.
• All 69 reference entries were read; that does not establish reading of their original papers. Earlier independently accepted source scopes remain.
• Named reviewers are acknowledged, but their reports were not read. The complete publisher version and correction history were not audited.
• Complete supplied text does not complete the illustrated article, all Nolan material, original recordings or the whole project.
• 101nodes=28DLBCL/30FL/15MZL/15MCL/13reactive controls; reactive nodes are not an unselected healthy population. CITE51/pairedflow13/independentflow50/TCR17 and24sample IKZF3 validation are not additive unique participants; exact overlaps retained.
• Imaging35cores from19patients, at most two cores per patient; millions of cells are nested. Some core-level proportions lack an explicit repeated-patient model. Five-and-a-half-million processed versus5,690,284 initial cells and50antibody/52marker wording remain qualified.
• Cell-marker boosting uses cell-level tenfold folds without explicit donor blocking. Separate sample-level nested leave-one-out entity classification reports74.5% balanced accuracy; authors do not claim diagnostic accuracy or external entity-classifier clinical validation.
• Independent retrospective DLBCL and prospective-GALLIUM-derived FL bulk data show observational survival associations. Data-derived maxstat cutoffs and literal maximized P value wording remain; locked threshold, FL survival n, hazard ratios/confidence intervals unestablished here. Genetic-analysis190/137counts are not every survival denominator.
• FL regulatory-cell survivalP0.17 is null and helper-cellP0.05 borderline; corrected genetic comparisons allP>0.05 despite displayed uncorrected results. ABC/GCB contrast is inconsistent across cohorts. Nulls do not prove equivalence.
• ExtendedData7 overall-survival title versus body/method progression-free endpoint, and d/e helper/regulatory panel references conflict. Native curves unviewed; do not choose a preferred endpoint or silently repair references.
• Pseudotime, inferred transcription factors, shared clonotypes and spatial proximity are associations, not lineage tracking, gene perturbation, active signalling or tested response to proposed therapy. Prior CAR-T/bispecific/transplant recipients excluded.
• No sample-size determination/randomization/blinding. Statistics no-data-excluded statement differs from earlier viability, treatment, contamination and cell/image-quality filtering; preanalytic/downstream scopes unreconciled. Treatment/age confounding retained.
• Nolan Resources/Supervision/Funding acquisition roles do not assign every grant to him or establish personal assay work. Correspondents/joint-supervisors Huber/Dietrich. Exact named BMBF/DFG/Heidelberg/EMBL/other recipients and Roche GALLIUM sponsorship preserved; original contracts unreviewed.
• Nolan declares Akoya cofounder/stockholder and US9909167 inventorship; Schürch EnableMedicine advisory/options/funding. Article-time disclosures are not current registry audit, proven bias, clinical treatment or classified UAP programme evidence.